Ovid Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Ovid Therapeutics Inc. (OVID) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $16.91 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-13
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $16.91M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $11.38M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $5.33M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $3.28M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2026-06-30 | $16.91M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $11.38M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $5.33M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $3.28M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $8.05K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-18 | |
| 2024-09-30 | $234.38K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $12.79K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $3.85M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $5.21M 10-K · filed 2026-03-18 | $5.21M 10-K · filed 2024-03-08 |
| 2023-09-30 | $11.56M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $5.85M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $1.03M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $62.16K 10-K · filed 2025-03-11 | |
| 2022-09-30 | $56.95K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $329.65K 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $3.08M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $2.39M 10-K · filed 2024-03-08 | |
| 2021-09-30 | $3.01M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $5.67M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $6.45M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $652.44K 10-K · filed 2023-03-13 | |
| 2020-09-30 | $10.47M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $18.22M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $2.02M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $4.49M 10-K · filed 2022-03-15 | |
| 2019-09-30 | $2.41M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $142.99K 10-Q · filed 2019-08-07 | |
| 2018-12-31 | $153.49K 10-K · filed 2021-03-15 | |
| 2018-09-30 | $380.23K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $1.67M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $1.04M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $8.17M 10-K · filed 2020-03-11 | |
| 2017-09-30 | $10.75M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $10.57M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $9.87M 10-Q · filed 2017-06-13 | |
| 2016-12-31 | $837.04K 10-K · filed 2019-03-07 | |
| 2015-12-31 | $780.50K 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |